Overall Survival (OS) and Relapse-Free Survival (RFS) in 349 patients with cytogenetically normal acute myeloid leukemia and <i>NPM1</i> mutation treated in the AMLCG99 study.

<p>(A) OS in patients with <i>NPM1</i> type A mutation versus <i>NPM1</i> rare type mutation. (B) OS in patients with <i>NPM1</i> type A mutation versus <i>NPM1</i> rare type mutation with or without an additional <i>FLT3-ITD</i>. (C) RFS in patients with <i>NPM1</i> type A mutation versus <i>NPM1</i> rare type mutation. (D) RFS in patients with <i>NPM1</i> type A mutation versus <i>NPM1</i> rare type mutation with or without an additional <i>FLT3-ITD</i>. <b>Abbreviations</b>: CR, complete remission; <i>FLT3-ITD</i>+, presence of an internal tandem duplication in the fms-related tyrosine 3 gene; <i>FLT3-ITD</i>-, absence of an internal tandem duplication in the fms-related tyrosine 3 gene; <i>NPM1-A</i>, mutation in the nucleophosmin gene consisting of an insertion of the tetranucleotide TCTG; <i>NPM1-RA</i>, mutation in the nucleophosmin gene other than type A.</p

Multivariable Cox regression models for OS and RFS in 349 <i>NPM1</i>-mutated patients.

<p>White blood cell count, platelet count, hemoglobin level, lactase dehydrogenase level, bone marrow blasts, de novo AML versus non de novo AML, performance status, sex, age, type A versus rare type <i>NPM1</i> mutation, <i>FLT3-ITD</i>, monoallelic <i>CEBPA</i> mutations, biallelic <i>CEBPA</i> mutations were included in the Cox regression models for OS and RFS with backward elimination. The analyses were performed using 313 patients for OS and 227 RFS who had data for all these variables. A p-value of <0.05 was considered as indicating significant differences. All parameters that did not have a significant impact on OS or RFS are not shown in the table, except for the <i>NPM1</i> mutation type.</p><p><b>Abbreviations</b>: <i>CEBPA</i>, CCAAT/enhancer-binding protein alpha gene; CI, confidence interval; <i>FLT3-ITD</i>, internal tandem duplication of the <i>FLT3</i> gene; HR, hazard ratio; negative, absence of <i>FLT3-ITD</i>; <i>NPM1</i>, nucleophosmin gene; <i>NPM1-A</i>, mutation in the nucleophosmin gene leading to the insertion of the tetranucleotide TCTG; <i>NPM1-RA</i>, mutation in the nucleophosmin gene other than type A; OS, Overall survival; p, p value; positive, presence of <i>FLT3-ITD</i>; RFS, Relapse-free survival; WBC, white blood cell count.</p><p>Multivariable Cox regression models for OS and RFS in 349 <i>NPM1</i>-mutated patients.</p